Shares of Eli Lilly surged 5.0% to $1,287.23 on August 19, pushing past the previous session's close of $1,225.73, as investors continued to bid up the stock following the registration of a Phase III clinical trial testing its once-monthly injectable, brenipatide, as an add-on treatment for major depressive disorder. The move extends a rally that began August 18, when Lilly jumped 3% on two separate deal announcements , giving the stock a 9% gain in five trading days.
A Weight-Loss Drug Mechanism Aimed at the Brain
Brenipatide is a once-monthly injectable that works on the same biological pathways as Lilly's blockbuster diabetes and obesity drugs Mounjaro and Zepbound, but is designed for monthly rather than weekly dosing. The critical difference: Lilly is leading with brain-focused conditions — alcohol addiction, bipolar disorder, and now depression — rather than the increasingly crowded obesity market.
Retrospective data from patients using similar drugs shows lower rates of depression and anxiety compared to matched controls , but every claim about brenipatide is currently based on trial design rather than trial data.
Depression Is a Huge, Poorly Served Market
Roughly seven out of ten people prescribed a standard antidepressant don't get adequate relief, and after trying two different medications, the odds of achieving remission drop to just 15–25%.
That affects 16 million Americans today. If brenipatide works, Lilly would have first-mover advantage in applying GLP-1 science — a drug class J.P. Morgan projects could reach $200 billion annually by 2030 — to mental health.
The Stock Is Already Priced for Perfection At $1,287, Lilly trades at roughly 40 times earnings, having become the first pharmaceutical company to cross a $1 trillion market cap.
Q2 2026 revenue grew 48% year-over-year , and management raised full-year guidance to $86 billion in revenue and $36 per share in earnings. But the depression trial's estimated primary completion date is February 2028 , meaning no data will emerge for at least 18 months.
The Bottom Line for Shareholders
Wall Street's consensus price target sits at $1,302.60 — barely above today's price. Investors are effectively paying now for a sprawling neuropsychiatric pipeline — spanning alcoholism, bipolar disorder, schizophrenia, opioid addiction, smoking, and depression — that remains entirely unproven. There is no confirmed FDA approval timeline; the earliest regulatory submission could come in 2027–2028. The enthusiasm is rational; the timeline demands patience.